Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aeterna Zentaris Changes Name to COSCIENS Biopharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aeterna Zentaris Changes Name to COSCIENS Biopharma

One of COSCIENS’ lead products is macimorelin, (Macrilen; Ghryvelin) an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, has changes its name effective August 6, 2024.
 
The shareholders of the company approved a special resolution authorizing the board of directors of the company to effect the name change. There is no change in the capitalization of the Company in connection with the name change.
 
One of COSCIENS’ lead products is macimorelin, (Macrilen; Ghryvelin) the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters